(NASDAQ: LGND) Ligand Pharmaceuticals's forecast annual revenue growth rate of 15.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Ligand Pharmaceuticals's revenue in 2025 is $187,584,000.On average, 4 Wall Street analysts forecast LGND's revenue for 2025 to be $4,161,858,623, with the lowest LGND revenue forecast at $4,024,545,527, and the highest LGND revenue forecast at $4,324,960,792. On average, 4 Wall Street analysts forecast LGND's revenue for 2026 to be $4,820,557,794, with the lowest LGND revenue forecast at $4,466,643,921, and the highest LGND revenue forecast at $5,153,895,280.
In 2027, LGND is forecast to generate $5,728,270,454 in revenue, with the lowest revenue forecast at $5,156,638,798 and the highest revenue forecast at $6,288,536,104.